Selected article for: "adaptive innate immune response and soluble form"

Author: Hajishengallis, George; Russell, Michael W.
Title: Innate Humoral Defense Factors
  • Cord-id: 8myto026
  • Document date: 2015_3_13
  • ID: 8myto026
    Snippet: Although innate immunity came into the research spotlight in the late 1990s when its instructive role in the adaptive immune response was recognized, innate humoral defense factors have a much older history. The exocrine secretions of the body contain a plethora of distinct soluble factors (lysozyme, lactoferrin, peroxidases, proline-rich proteins, histatins, etc.) that protect the body from mucosal microbial pathogens. More recent studies have established that the humoral arm of innate immunity
    Document: Although innate immunity came into the research spotlight in the late 1990s when its instructive role in the adaptive immune response was recognized, innate humoral defense factors have a much older history. The exocrine secretions of the body contain a plethora of distinct soluble factors (lysozyme, lactoferrin, peroxidases, proline-rich proteins, histatins, etc.) that protect the body from mucosal microbial pathogens. More recent studies have established that the humoral arm of innate immunity contains a heterogeneous group of pattern-recognition molecules (e.g., pentraxins, collectins, and ficolins), which perform diverse host-defense functions, such as agglutination and neutralization, opsonization, control of inflammation, and complement activation and regulation. These pattern-recognition molecules, which act as functional predecessors of antibodies (“ante-antibodies”), and the classic soluble innate defense factors form an integrated system with complementary specificity, action, and tissue distribution, and they are the subject of this chapter.

    Search related documents:
    Co phrase search for related documents
    • active site and additional specificity: 1
    • active site and lung injury: 1, 2
    • acute phase and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8
    • acute phase and adaptive immune response activation: 1
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and adaptive immunity activation: 1
    • acute phase and liver release: 1, 2
    • acute phase and local inflammation: 1, 2
    • acute phase and long pentraxin: 1
    • acute phase and long short: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute phase and low concentration: 1, 2, 3
    • acute phase and low molecular weight: 1, 2, 3, 4, 5, 6, 7
    • acute phase and low tendency: 1
    • acute phase and lps binding: 1, 2
    • acute phase and lps response: 1, 2, 3
    • acute phase and lung epithelial cell: 1
    • acute phase and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute phase and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38
    • acute phase and lung surfactant: 1, 2